Skip to content
Screener

Citius Oncology, Inc. CTOR Q1 2026 earnings

Reported February 13, 2026 · Before market open

Revenue$3.9MMiss by $428.9K
EPS-$0.06Miss by $0.02
Revenue estimate$4.4M
EPS estimate-$0.04

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full
Revenue$3.9M—
Gross profit$3.2M—
Operating income-$5.3M+17.9%
Net income-$5.5M+16.9%
EPS (diluted)-$0.06+33.3%

Balance sheet

See full
Cash & equivalents$7.3M+6,513,696%
Total equity$58.4M+41.5%
Total assets$110.0M+21.5%

Cash flow

See full
Operating cash flow-$7.4M-436%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$84.8M+3.1%

Returns & leverage

See full
Return on equity-47.4%-12.1pp
Current ratio0.8×+0.4×

FAQ

When did Citius Oncology, Inc. report Q1 2026 earnings?
Citius Oncology, Inc. (CTOR) reported Q1 2026 earnings on February 13, 2026 before market open.
What were Citius Oncology, Inc.'s Q1 2026 revenue and EPS?
Citius Oncology, Inc. reported revenue of $3.9M and eps of $-0.06 for Q1 2026.
Did Citius Oncology, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $4.4M by $428.9K. EPS missed the consensus estimate of $-0.04 by $0.02.
How did Citius Oncology, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 45.5% from $-0.11.
Where can I find Citius Oncology, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-015894) and the 10-Q periodic report (0001213900-26-015877) directly on SEC EDGAR. The filing index links above go to sec.gov.